|
"楊志新"的相關文件
顯示項目 86-95 / 209 (共21頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2013 |
Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study
|
Chang, Gee-Chen; Tsai, Chun-Ming; Hsia, Te-Chun; Yang, Chih-Hsin; Abdulnabi, Radhi; Blair, Julie M.; Linn, Carlos; 楊志新 |
| 國立臺灣大學 |
2013 |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
|
Huang, Ming-Hung; Lee, Jih-Hsiang; Chang, Ya-Ju; Tsai, Hsin-Hui; Lin, Yu-Lin; Lin, Anya Maan-Yuh; Yang, James Chih-Hsin; 楊志新; 林育麟; 李日翔 |
| 國立臺灣大學 |
2013 |
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
|
Yang, James Chih-Hsin; Hirsh, Vera; Schuler, Martin; Yamamoto, Nobuyuki; O'Byrne, Kenneth J.; Mok, Tony S. K.; Zazulina, Victoria; Shahidi, Mehdi; Lungershausen, Juliane; Massey, Dan; Palmer, Michael; Sequist, Lecia V.; 楊志新 |
| 國立臺灣大學 |
2013 |
Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinib
|
Yang, J. Chih-Hsin; Sequist, L.; O'Byrne, K.; Schuler, M.; Mok, T.; Geater, S.; Massey, D.; O'Brien, D.; Zazulina, V.; Wu, Y. L.; 楊志新 |
| 國立臺灣大學 |
2013 |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
Kao, Hsiang-Fong; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新; 高祥豐 |
| 國立臺灣大學 |
2013 |
Diarrhea associated with afatinib: an oral ErbB family blocker
|
Yang, James Chih-Hsin; Reguart, Noemi; Barinoff, Jana; Koehler, Jens; Uttenreuther-Fischer, Martina; Stammberger, Uz; O'Brien, Dennis; Wolf, Juergen; Cohen, Ezra E. W.; 楊志新 |
| 國立臺灣大學 |
2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S. K.; Saijo, Nagahiro; Thongprasert, Sumitra; Yang, James C. H.; Chu, Da-Tong; Yang, Jin-Ji; Rukazenkov, Yuri; 楊志新 |
| 國立臺灣大學 |
2013 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, Lecia V.; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin; 楊志新 |
| 國立臺灣大學 |
2012 |
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
|
Wu, Shang-Gin; Kuo, Yao-Wen; Chang, Yih-Leong; Shih, Jin-Yuan; Chen, Ya-Hui; Tsai, Meng-Feng; Yu, Chong-Jen; Yang, Chih-Hsin; Yang, Pan-Chyr; 楊志新; 張逸良; 楊泮池; 余忠仁; 郭耀文; 吳尚俊; 施金元; 陳盈憲 |
| 國立臺灣大學 |
2012 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
|
Yang, James Chih-Hsin; Shih, Jin-Yuan; Su, Wu-Chou; Hsia, Te-Chun; Tsai, Chun-Ming; Ou, Sai-Hong Ignatius; Yu, Chung-Jen; Chang, Gee-Chen; Ho, Ching-Liang; Sequist, Lecia V.; Dudek, Arkadiusz Z.; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, Pan-Chyr; Miller, Vincent A.; 楊志新; 楊泮池; 余忠仁; 施金元 |
顯示項目 86-95 / 209 (共21頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目
|
